Cough is a protective reflex which help to remove any foreign material and excessive mucous produced during the inflammation of the respiratory lining. However, cough impairs the quality of life in terms of disturbances in sleep, daily activities and social stigmata. Cough reflex is complex, which involves central and peripheral nervous system as well as the smooth muscles of the bronchial tree. This results in bronchoconstriction, which in turn increase the sensitivity of the cough receptors. The supplementary role of Bronchodilatory Cough formulation in offering effective control of associated symptoms has been well highlighted. These bronchodilators have been suggested to offer ancillary actions that go beyond bronchodilation including differential impact on cough sensitivity, clearance of cough secretions while reducing protrusive inflammatory mediators’ release that is so common in these inflammatory conditions. At the same time these hyper mucosecretory states are better controlled by a combination of mucolytics/expectorants with bronchodilators. The complimentary action of the mucolytics with bronchodilator including Terbutaline improves sputum viscosity and mucociliary clearance or expulsion for better control of productive cough symptoms.

Data regarding use of oral bronchodilator based cough formulations (BCF) and/or xanthines in management of Bronchial asthma symptoms including cough remains unexplored.

To further assess the real world utilization of treatment strategies for Cough clearance in Bronchial asthma cases an observational, drug utilization, case control, concurrent analyses is planned.